6 citations
,
December 2020 in “Dermatological reviews”
This review discusses the potential link between androgenic alopecia, androgens, and the severity of COVID-19, highlighting possible therapeutic targets but reports no new clinical results.
April 2025 in “International Journal of Clinical Research and Reports”
This study conducted on hyper-androgenic infertile overweight women found that lifestyle modifications significantly improved androgenic alopecia levels, as evidenced by a decrease in stage III androgenic alopecia cases after the intervention.
This study investigates the role of AR up-regulation in the pathogenesis of androgenetic alopecia, but it remains unclear if HSP27 and miR-1 are jointly involved.
122 citations
,
November 2010 in “Journal of Dermatological Science”
This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.
63 citations
,
August 2008 in “Journal of Cosmetic Dermatology”
The researchers reported that the petroleum ether extract of Cuscuta reflexa may promote hair growth in testosterone-induced alopecia in mice by inhibiting the enzyme 5α-reductase.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.
Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.
Does metformin help control DHT levels that trigger androgenic alopecia?Metformin has been shown to lower circulating androgens in women with PCOS, but no published study has measured scalp DHT, 5-alpha reductase activity in the follicle, or hair density in anyone taking it — so its effect on pattern hair loss is untested, and it is not a DHT blocker.
highly targeted anti-androgen that might have minimal systemic effects
What is pyrilutamide, and how does it help with androgenic alopecia or hair loss caused by DHT?Pyrilutamide (KX-826) is an investigational topical antiandrogen designed to block DHT at the androgen receptor in the scalp rather than lower DHT in the blood. Its sponsor has announced positive Phase III top-line results in China, but none of the data are peer-reviewed and it is not approved as a medicine anywhere.